{"url_path":"/sec/imdx/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1642380/0001642380-26-000008-index.html","accession_number":"0001642380-26-000008","cik":"0001642380","ticker":"IMDX","issuer_name":"Insight Molecular Diagnostics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1642380/0001642380-26-000008-index.html","primary_entity_key":"0001642380","primary_entity_name":"Insight Molecular Diagnostics Inc."},"word_count":1225,"has_tables":true,"body_markdown":"10-Q\n\nfalse--12-31Q10001642380http://fasb.org/us-gaap/2025#RelatedPartyMemberhttp://fasb.org/us-gaap/2025#RelatedPartyMemberhttp://imdxinc.com/20260331#OperatingAndFinancingLeaseLiabilitiesCurrent http://imdxinc.com/20260331#OperatingAndFinancingLeaseLiabilitiesNoncurrenthttp://imdxinc.com/20260331#OperatingAndFinancingLeaseLiabilitiesCurrent http://imdxinc.com/20260331#OperatingAndFinancingLeaseLiabilitiesNoncurrenthttp://imdxinc.com/20260331#OperatingAndFinancingLeaseLiabilitiesCurrent http://imdxinc.com/20260331#OperatingAndFinancingLeaseLiabilitiesNoncurrenthttp://imdxinc.com/20260331#OperatingAndFinancingLeaseLiabilitiesCurrent http://imdxinc.com/20260331#OperatingAndFinancingLeaseLiabilitiesNoncurrent0http://imdxinc.com/20260331#ChiefExecutiveOfficerAndChiefFinancialOfficerMember0001642380country:US2026-01-012026-03-310001642380imdx:InsightGeneticsIncMemberimdx:RoyaltyTwoMember2026-03-310001642380imdx:OfficeLeaseAgreementMember2019-12-232019-12-230001642380imdx:OfficeLeaseAgreementMember2019-12-230001642380us-gaap:RetainedEarningsMember2024-12-310001642380us-gaap:CommonStockMember2026-03-310001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMembersrt:MaximumMember2024-10-040001642380srt:MaximumMember2026-03-310001642380imdx:BioRadLaboratoriesIncMemberimdx:LaboratoryEquipmentMember2025-03-310001642380imdx:FinancingLeaseArrangementForEquipmentMemberimdx:NewEquipmentMembersrt:MaximumMember2025-08-012025-08-310001642380imdx:MPEEMValuationApproachMemberimdx:DetermaIOMember2025-12-310001642380imdx:FinancingLeaseArrangementForEquipmentMemberimdx:InternationalEquipmentMembersrt:MaximumMember2025-08-012025-08-310001642380imdx:DragonScientificLLCMemberimdx:RazorStockPurchaseAgreementMemberimdx:RazorGenomicsIncMember2023-02-160001642380us-gaap:SalesRevenueNetMemberimdx:CompanyAMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-03-310001642380imdx:DetermaCNIMemberimdx:MPEEMValuationApproachMember2025-12-310001642380us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2024-04-152024-04-150001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMemberimdx:PatrickWSmithMember2025-02-102025-02-100001642380imdx:DetermaIOMember2025-01-012025-12-310001642380us-gaap:MachineryAndEquipmentMembersrt:MinimumMember2026-03-3100016423802026-01-012026-03-310001642380us-gaap:FairValueInputsLevel3Memberimdx:InsightGeneticsIncMembersrt:MaximumMemberus-gaap:MeasurementInputExpectedTermMember2025-01-012025-03-310001642380imdx:CostOfRevenuesMember2026-01-012026-03-310001642380us-gaap:StockOptionMember2026-01-012026-03-310001642380imdx:PreFundedWarrantMember2026-03-3100016423802026-05-040001642380imdx:SecuritiesPurchaseAgreementMemberimdx:BioRadLaboratoriesIncMemberus-gaap:CommonStockMember2025-02-102025-02-100001642380imdx:MachineryEquipmentAndLeaseholdImprovementsMember2025-12-310001642380imdx:SecuritiesPurchaseAgreementMemberimdx:PreFundedWarrantMember2026-02-120001642380imdx:FinancingLeaseArrangementForEquipmentMemberimdx:InternationalEquipmentSaleAndLeasebackMember2025-08-012025-08-310001642380imdx:MPEEMValuationApproachMemberimdx:DetermaIOMember2025-01-012025-12-310001642380imdx:MergerAgreementMemberimdx:ChronixEquityMember2023-02-072023-02-080001642380imdx:CustomerOneMemberus-gaap:CustomerConcentrationRiskMemberimdx:PurchasesMember2026-01-012026-03-310001642380imdx:NashvilleOfficeAndFacilitiesLeasesMember2026-03-310001642380imdx:TwoThousandTenPlanAndTwoThousandEighteenIncentivePlanActivityMember2026-03-310001642380us-gaap:FairValueInputsLevel3Memberimdx:InsightGeneticsIncMember2026-01-012026-03-310001642380imdx:PreFundedWarrantMember2026-02-120001642380us-gaap:MachineryAndEquipmentMembersrt:MaximumMember2026-03-310001642380imdx:TwoThousandTenPlanAndTwoThousandEighteenIncentivePlanActivityMember2026-01-012026-03-310001642380imdx:OfficeSubleaseAgreementMember2023-08-080001642380us-gaap:SalesRevenueNetMemberus-gaap:NonUsMemberus-gaap:ProductConcentrationRiskMember2025-01-012025-03-310001642380imdx:ExecutiveOfficersMember2025-01-012025-12-310001642380imdx:FinancingLeaseArrangementForEquipmentMemberimdx:NewEquipmentMember2025-08-012025-08-310001642380imdx:NashvilleOfficeAndFacilitiesLeasesMember2024-01-012024-01-310001642380imdx:KittedProductsMember2026-01-012026-03-310001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMember2023-04-032023-04-030001642380us-gaap:FairValueInputsLevel3Memberimdx:InsightGeneticsIncMember2024-12-310001642380srt:AsiaPacificMember2026-03-310001642380imdx:ChronixAcquisitionMember2026-01-012026-03-310001642380imdx:CustomerOneMemberus-gaap:CustomerConcentrationRiskMemberimdx:PurchasesMember2025-01-012025-03-310001642380us-gaap:CommonStockMember2025-03-310001642380imdx:RazorStockPurchaseAgreementMemberimdx:RazorGenomicsIncMember2023-02-160001642380imdx:SecuritiesPurchaseAgreementMemberimdx:PreFundedWarrantMember2025-02-100001642380imdx:KittedProductsMember2025-01-012025-03-310001642380us-gaap:SellingAndMarketingExpenseMember2026-01-012026-03-3100016423802024-04-050001642380imdx:SecuritiesPurchaseAgreementMemberimdx:PreFundedWarrantMember2026-02-122026-02-120001642380country:US2025-01-012025-03-310001642380imdx:NashvilleOfficeAndFacilitiesLeasesMember2025-09-012025-09-300001642380imdx:BroadwoodPartnersLPMemberimdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMember2024-04-152024-04-150001642380imdx:OperatingAndFinancingLeasesMember2025-12-310001642380imdx:TwoThousandTenStockOptionPlanMember2025-12-310001642380imdx:TwoThousandTenPlanAndTwoThousandEighteenIncentivePlanActivityMember2025-01-012025-12-310001642380imdx:LaboratoryServicesMember2025-12-310001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMember2024-04-150001642380imdx:ChronixMergerMemberus-gaap:FairValueInputsLevel3Member2024-12-310001642380imdx:OfficeLeaseAgreementMember2021-06-212021-06-210001642380imdx:CustomerOneMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-12-310001642380imdx:ChronixMergerMember2025-03-310001642380us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001642380imdx:UnderwrittenOfferingMemberimdx:PuraVidaInvestmentsLLCMember2022-04-130001642380imdx:OfficeLeaseAgreementMember2025-01-020001642380us-gaap:FairValueInputsLevel3Memberimdx:ChronixMergerMemberus-gaap:MeasurementInputDiscountRateMembersrt:MaximumMember2025-03-310001642380imdx:OfficeSubleaseAgreementMember2026-03-310001642380imdx:LaboratoryServicesMember2026-01-012026-03-310001642380imdx:KittedProductsMember2026-03-310001642380imdx:PerformanceBasedRestrictedStockUnitsMemberimdx:MonteCarloValuationTechniqueMember2024-10-012024-10-310001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMemberimdx:ArnoMember2024-04-152024-04-150001642380imdx:KittedProductsMember2025-12-310001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMemberimdx:PatrickWSmithMember2024-10-042024-10-040001642380imdx:ExecutiveOfficersMember2026-01-012026-03-310001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMember2026-02-120001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2026-01-012026-03-310001642380us-gaap:FairValueInputsLevel3Memberimdx:MeasurementInputManagementProbabilityEstimateMemberimdx:InsightGeneticsIncMembersrt:MaximumMember2025-03-310001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMember2025-02-102025-02-100001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMember2025-02-100001642380imdx:SecuritiesPurchaseAgreementMemberimdx:BioRadLaboratoriesIncMemberus-gaap:CommonStockMember2026-02-122026-02-120001642380us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMembercountry:US2026-01-012026-03-310001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMember2023-04-030001642380imdx:BioRadLaboratoriesIncMember2026-03-310001642380us-gaap:EquipmentMembersrt:MinimumMember2026-03-310001642380imdx:SecuritiesPurchaseAgreementMemberimdx:BioRadLaboratoriesIncMemberus-gaap:CommonStockMember2024-10-042024-10-040001642380us-gaap:ShareBasedCompensationAwardTrancheTwoMemberimdx:PerformanceBasedRestrictedStockUnitsMember2024-10-012024-10-310001642380us-gaap:FairValueInputsLevel3Membersrt:MinimumMemberimdx:MeasurementInputManagementProbabilityEstimateMemberimdx:InsightGeneticsIncMember2026-03-310001642380imdx:JamesMemberimdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMember2024-10-042024-10-040001642380us-gaap:ShareBasedCompensationAwardTrancheTwoMemberimdx:PerformanceBasedRestrictedStockUnitsMemberimdx:MonteCarloValuationTechniqueMember2024-10-012024-10-310001642380srt:AsiaPacificMember2025-12-310001642380imdx:ChronixMergerMemberus-gaap:FairValueInputsLevel3Membersrt:MinimumMemberus-gaap:MeasurementInputExpectedTermMember2025-01-012025-03-310001642380us-gaap:CustomerRelationshipsMember2025-01-012025-03-310001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMemberimdx:SchutzMember2024-10-042024-10-040001642380imdx:OfficeSubleaseAgreementMember2023-08-082023-08-080001642380imdx:PerformanceBasedRestrictedStockUnitsMemberimdx:MonteCarloValuationTechniqueMember2025-10-312025-10-310001642380imdx:PuraVidaMemberimdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMember2023-04-032023-04-030001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMemberimdx:AWMMember2023-04-032023-04-030001642380imdx:BioRadLaboratoriesIncMemberimdx:LaboratoryEquipmentMember2025-01-012025-03-310001642380us-gaap:CommonStockMember2025-12-310001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberimdx:KittedProductsMember2026-01-012026-03-310001642380us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2024-04-150001642380us-gaap:FairValueInputsLevel3Memberimdx:InsightGeneticsIncMembersrt:MaximumMemberus-gaap:MeasurementInputExpectedTermMember2026-01-012026-03-310001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMember2024-04-152024-04-150001642380imdx:DragonScientificLLCMemberimdx:RazorStockPurchaseAgreementMemberimdx:RazorGenomicsIncMember2022-12-152022-12-150001642380imdx:TwoThousandTenStockOptionPlanMember2026-03-310001642380us-gaap:RetainedEarningsMember2025-01-012025-03-310001642380imdx:UnderwrittenOfferingMemberimdx:UnderwritersMemberimdx:BroadwoodCapitalLPMember2022-04-130001642380imdx:FinancingLeaseArrangementForEquipmentMember2025-08-012025-08-310001642380us-gaap:GeneralAndAdministrativeExpenseMember2026-01-012026-03-310001642380us-gaap:FairValueInputsLevel3Membersrt:MinimumMemberimdx:MeasurementInputManagementProbabilityEstimateMemberimdx:InsightGeneticsIncMember2025-03-310001642380us-gaap:CommonStockMember2024-12-310001642380us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001642380srt:MinimumMember2026-03-310001642380country:US2026-03-310001642380imdx:MachineryEquipmentAndLeaseholdImprovementsMember2026-03-310001642380country:US2025-12-310001642380us-gaap:EquipmentMembersrt:MaximumMember2026-03-310001642380imdx:SecuritiesPurchaseAgreementMember2025-02-102025-02-100001642380country:GB2025-12-310001642380us-gaap:FairValueInputsLevel3Membersrt:MinimumMemberimdx:InsightGeneticsIncMemberus-gaap:MeasurementInputExpectedTermMember2026-01-012026-03-310001642380imdx:ChronixAcquisitionMember2025-01-012025-12-310001642380imdx:DetermaCNIMember2025-01-012025-12-310001642380imdx:InsightGeneticsIncMemberimdx:MilestoneOneMember2026-03-310001642380imdx:SecuritiesPurchaseAgreementMemberimdx:JamesMemberus-gaap:CommonStockMember2025-02-102025-02-100001642380us-gaap:FairValueInputsLevel3Memberimdx:InsightGeneticsIncMember2025-01-012025-03-310001642380imdx:InsightGeneticsIncMemberimdx:MilestoneTwoMember2026-03-310001642380imdx:LaboratoryServicesMember2025-01-012025-03-310001642380us-gaap:RetainedEarningsMember2026-03-310001642380imdx:BioRadLaboratoriesIncMember2025-12-310001642380imdx:NashvilleOfficeAndFacilitiesLeasesMember2024-01-310001642380us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-3100016423802026-03-310001642380imdx:GermanyOfficeAndFacilitiesLeasesMember2025-08-012025-08-310001642380imdx:OperatingAndFinancingLeasesMember2026-03-310001642380us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001642380imdx:ChronixMergerMember2026-01-012026-03-310001642380imdx:FinancingLeaseArrangementForEquipmentMemberimdx:SaleAndLeasebackMembersrt:MaximumMember2025-08-012025-08-310001642380imdx:ChronixMergerMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMembersrt:MaximumMember2026-03-310001642380imdx:GermanyOfficeAndFacilitiesLeasesMember2025-08-310001642380us-gaap:FairValueInputsLevel3Memberimdx:MeasurementInputManagementProbabilityEstimateMemberimdx:InsightGeneticsIncMembersrt:MaximumMember2026-03-310001642380us-gaap:CommonStockMember2024-04-150001642380us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001642380imdx:BroadwoodPartnersLPMemberimdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMember2025-02-102025-02-100001642380imdx:PerformanceBasedRestrictedStockUnitsMember2024-10-310001642380us-gaap:RetainedEarningsMember2026-01-012026-03-310001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMemberimdx:ArnoMember2023-04-032023-04-030001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMemberimdx:UnterbergLegacyCapitalLLCMember2025-02-102025-02-100001642380imdx:UnderwrittenOfferingMemberus-gaap:CommonStockMemberimdx:PuraVidaInvestmentsLLCMember2022-04-122022-04-130001642380imdx:UnderwrittenOfferingMemberus-gaap:CommonStockMemberimdx:BroadwoodCapitalLPMember2022-04-122022-04-130001642380us-gaap:WarrantMember2025-01-012025-03-310001642380us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2025-02-100001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberimdx:KittedProductsMember2025-01-012025-03-310001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMemberimdx:AWMMember2025-02-102025-02-100001642380us-gaap:FairValueInputsLevel3Memberimdx:InsightGeneticsIncMember2026-03-310001642380us-gaap:CommonStockMember2025-02-100001642380us-gaap:ValuationTechniqueDiscountedCashFlowMemberimdx:InsightGeneticsIncMember2026-01-012026-03-310001642380imdx:SecuritiesPurchaseAgreementMember2026-02-122026-02-120001642380imdx:BioRadLaboratoriesIncMemberimdx:LaboratoryEquipmentMember2026-01-012026-03-310001642380imdx:LaboratoryServicesMember2026-03-310001642380imdx:TwoThousandEighteenIncentivePlanMember2025-12-310001642380imdx:UnderwrittenOfferingMemberimdx:BroadwoodCapitalLPMembersrt:MaximumMember2022-04-122022-04-130001642380imdx:LaboratoryServicesMember2025-01-012025-03-310001642380imdx:PerformanceBasedRestrictedStockUnitsMember2024-10-012024-10-310001642380us-gaap:SellingAndMarketingExpenseMember2025-01-012025-03-310001642380imdx:ChronixMergerMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMembersrt:MinimumMember2026-03-310001642380imdx:SecuritiesPurchaseAgreementMemberimdx:PreFundedWarrantMember2025-02-102025-02-100001642380us-gaap:RetainedEarningsMember2025-03-310001642380imdx:BroadwoodPartnersLPMemberimdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMember2026-02-122026-02-120001642380us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2025-02-102025-02-100001642380srt:EuropeMember2026-03-310001642380us-gaap:ValuationTechniqueDiscountedCashFlowMemberimdx:ChronixMergerMember2026-01-012026-03-310001642380imdx:SecuritiesPurchaseAgreementMemberimdx:BioRadLaboratoriesIncMemberus-gaap:CommonStockMember2024-04-152024-04-150001642380imdx:OfficeSubleaseAgreementMember2026-01-012026-03-310001642380imdx:SubleasePeriodFourMemberimdx:OfficeSubleaseAgreementMember2026-01-012026-03-310001642380us-gaap:ResearchAndDevelopmentExpenseMember2026-01-012026-03-310001642380imdx:PerformanceBasedRestrictedStockUnitsMemberus-gaap:ShareBasedCompensationAwardTrancheOneMemberimdx:MonteCarloValuationTechniqueMember2024-10-012024-10-310001642380imdx:MonthlyRentMemberimdx:OfficeLeaseAgreementMember2019-12-232019-12-230001642380imdx:RazorStockPurchaseAgreementMemberimdx:RazorGenomicsIncMember2023-02-152023-02-160001642380imdx:BroadwoodPartnersLPMemberimdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMember2024-10-042024-10-040001642380imdx:KittedProductsMember2025-01-012025-03-310001642380imdx:LifeTechnologiesCorporationMember2026-01-012026-03-310001642380imdx:ChronixMergerMemberus-gaap:FairValueInputsLevel3Member2025-03-310001642380imdx:ChronixMember2026-01-012026-03-310001642380imdx:UnderwrittenOfferingMembersrt:MaximumMemberimdx:PuraVidaInvestmentsLLCMember2022-04-130001642380imdx:FinancingLeaseArrangementForEquipmentMemberimdx:NewEquipmentMember2025-08-310001642380imdx:MPEEMValuationApproachMemberimdx:DetermaIOMember2026-01-012026-03-310001642380imdx:PerformanceBasedRestrictedStockUnitsMember2025-10-312025-10-310001642380imdx:BioRadLaboratoriesIncMemberimdx:LaboratoryEquipmentMember2026-03-310001642380imdx:InsightGeneticsIncMember2026-03-310001642380us-gaap:FairValueInputsLevel3Membersrt:MinimumMemberus-gaap:MeasurementInputDiscountRateMemberimdx:InsightGeneticsIncMember2025-03-310001642380us-gaap:CommonStockMember2026-01-012026-03-310001642380us-gaap:SalesRevenueNetMemberimdx:CompanyAMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-03-310001642380us-gaap:FairValueInputsLevel3Membersrt:MinimumMemberimdx:InsightGeneticsIncMemberus-gaap:MeasurementInputExpectedTermMember2025-01-012025-03-310001642380imdx:SecuritiesPurchaseAgreementMemberimdx:PreFundedWarrantMember2024-04-152024-04-150001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberimdx:LaboratoryServicesMember2026-01-012026-03-310001642380us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberimdx:InsightGeneticsIncMember2026-03-310001642380imdx:NashvilleOfficeAndFacilitiesLeasesMemberimdx:MonthlyRentMember2024-01-012024-01-310001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMember2024-10-040001642380imdx:SubleasePeriodTwoMemberimdx:OfficeSubleaseAgreementMember2026-01-012026-03-310001642380imdx:InvestorRelationsConsultingServiceArrangementMember2026-01-012026-03-310001642380country:GB2026-03-310001642380imdx:FinancingLeaseArrangementForEquipmentMemberimdx:InternationalEquipmentSaleAndLeasebackMember2025-08-310001642380imdx:BroadwoodPartnersLPMemberimdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMember2023-04-032023-04-030001642380imdx:SecuritiesPurchaseAgreementMember2024-10-042024-10-040001642380srt:EuropeMember2025-12-310001642380imdx:TwoThousandTenPlanAndTwoThousandEighteenIncentivePlanActivityMember2025-01-012025-03-310001642380us-gaap:FairValueInputsLevel3Memberimdx:InsightGeneticsIncMember2025-03-310001642380us-gaap:WarrantMember2017-02-280001642380us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2025-01-012025-03-310001642380us-gaap:FairValueInputsLevel3Memberimdx:ChronixMergerMembersrt:MaximumMemberus-gaap:MeasurementInputExpectedTermMember2026-01-012026-03-310001642380us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberimdx:InsightGeneticsIncMembersrt:MaximumMember2025-03-310001642380imdx:InsightGeneticsIncMember2026-01-012026-03-310001642380us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2026-02-122026-02-120001642380imdx:LaboratoryServicesMember2026-01-012026-03-310001642380imdx:MilestoneThreeMemberimdx:InsightGeneticsIncMember2026-03-3100016423802025-03-310001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberimdx:LaboratoryServicesMember2025-01-012025-03-310001642380imdx:KittedProductsMember2026-01-012026-03-310001642380us-gaap:FairValueInputsLevel3Memberimdx:InsightGeneticsIncMember2025-12-310001642380us-gaap:AccountsPayableMemberimdx:CustomerOneMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-12-310001642380us-gaap:StockOptionMember2025-01-012025-03-310001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMemberimdx:AWMMember2024-10-042024-10-040001642380us-gaap:FairValueInputsLevel3Memberimdx:ChronixMergerMember2025-12-3100016423802024-12-310001642380imdx:MonthlyRentMemberimdx:OfficeSubleaseAgreementMember2026-01-012026-03-3100016423802024-04-052024-04-050001642380imdx:ChronixMergerMemberus-gaap:FairValueInputsLevel3Member2026-01-012026-03-310001642380imdx:NashvilleOfficeAndFacilitiesLeasesMember2025-09-300001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMember2026-02-122026-02-120001642380imdx:UnderwrittenOfferingMemberimdx:BroadwoodCapitalLPMember2022-04-130001642380imdx:CostOfRevenuesMember2025-01-012025-03-310001642380us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001642380imdx:SubleasePeriodFiveMemberimdx:OfficeSubleaseAgreementMember2026-01-012026-03-310001642380us-gaap:FairValueInputsLevel3Memberimdx:ChronixMergerMember2025-01-012025-03-310001642380us-gaap:AccountsPayableMemberus-gaap:CustomerConcentrationRiskMemberimdx:CustomerTwoMember2025-01-012025-12-310001642380imdx:SubleasePeriodOneMemberimdx:OfficeSubleaseAgreementMember2026-01-012026-03-310001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMemberimdx:UnterbergLegacyCapitalLLCMember2024-10-042024-10-040001642380us-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-03-310001642380imdx:CustomerOneMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-03-310001642380us-gaap:CommonStockMember2025-01-012025-03-310001642380imdx:PerformanceBasedRestrictedStockUnitsMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-10-012024-10-310001642380us-gaap:SalesRevenueNetMemberus-gaap:NonUsMemberus-gaap:ProductConcentrationRiskMember2026-01-012026-03-310001642380imdx:RazorGenomicsIncMember2021-02-230001642380us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001642380imdx:UnderwrittenOfferingMemberimdx:UnderwritersMemberimdx:PuraVidaInvestmentsLLCMember2022-04-122022-04-130001642380imdx:TwoThousandEighteenIncentivePlanMember2026-03-310001642380imdx:TwoThousandTenPlanAndTwoThousandEighteenIncentivePlanActivityMember2025-12-310001642380imdx:SecuritiesPurchaseAgreementMemberimdx:PreFundedWarrantMember2026-03-310001642380imdx:LaboratoryServicesMember2024-12-310001642380us-gaap:WarrantMember2026-01-012026-03-310001642380imdx:SubleasePeriodThreeMemberimdx:OfficeSubleaseAgreementMember2026-01-012026-03-310001642380imdx:PerformanceBasedRestrictedStockUnitsMemberimdx:MonteCarloValuationTechniqueMember2026-01-012026-03-310001642380imdx:ChronixMergerMemberus-gaap:FairValueInputsLevel3Membersrt:MinimumMemberus-gaap:MeasurementInputDiscountRateMember2025-03-310001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMemberimdx:ArnoMemberimdx:MrGutfreundMember2023-04-032023-04-030001642380imdx:TwoThousandEighteenIncentivePlanMember2026-01-012026-03-310001642380imdx:DragonScientificLLCMemberimdx:RazorStockPurchaseAgreementMemberimdx:RazorGenomicsIncMember2022-12-150001642380us-gaap:FairValueInputsLevel3Memberimdx:ChronixMergerMembersrt:MaximumMemberus-gaap:MeasurementInputExpectedTermMember2025-01-012025-03-310001642380imdx:SecuritiesPurchaseAgreementMemberimdx:PreFundedWarrantMember2024-04-150001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMemberimdx:AWMMember2024-04-152024-04-150001642380imdx:ChronixMergerMember2026-03-3100016423802025-01-012025-03-310001642380imdx:RoyaltyOneMemberimdx:InsightGeneticsIncMember2026-03-310001642380us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-3100016423802025-12-310001642380us-gaap:FairValueInputsLevel3Memberimdx:ChronixMergerMembersrt:MinimumMemberus-gaap:MeasurementInputExpectedTermMember2026-01-012026-03-310001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMemberimdx:SchutzMember2025-02-102025-02-100001642380us-gaap:FairValueInputsLevel3Memberimdx:ChronixMergerMember2026-03-310001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMembercountry:US2025-01-012025-03-310001642380us-gaap:WarrantMember2019-10-310001642380us-gaap:WarrantMember2017-03-310001642380imdx:FinancingLeaseArrangementForEquipmentMember2025-08-310001642380us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310001642380us-gaap:RetainedEarningsMember2025-12-310001642380us-gaap:AccountsPayableMemberimdx:CustomerOneMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-03-31imdx:Segmentxbrli:pureutr:sqftxbrli:sharesiso4217:USDxbrli:sharesiso4217:USD\n\n[Table of Contents](#toc_page)\n\n \n\n \n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWashington, D.C. 20549\n\n \n\nFORM 10-Q\n\n \n\n☒\n\nQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n \n\nFor the quarterly period ended March 31, 2026\n\nOR\n\n \n\n☐\n\nTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n \n\nFor the transition period from ___________ to __________\n\n \n\nCommission File Number: 001-37648\n\n \n\nInsight Molecular Diagnostics Inc.\n\n(Exact name of registrant as specified in its charter)\n\n \n\nCalifornia\n\n \n\n27-1041563\n\n(State or other jurisdiction\n\n \n\n(I.R.S. Employer\n\nof incorporation or organization)\n\n \n\nIdentification No.)\n\n \n\n2 International Plaza Dr., Suite 510\n\nNashville, Tennessee 37217\n\n(Address of principal executive offices) (Zip Code)\n\n \n\n(615) 255-8880\n\n(Registrant’s telephone number, including area code)\n\n \n\nN/A\n\n(Former name, former address and former fiscal year, if changed since last report)\n\n \n\nSecurities registered pursuant to Section 12(b) of the Exchange Act:\n\n \n\nTitle of each class\n\n \n\nTrading Symbol\n\n \n\nName of each exchange on which registered\n\nCommon Stock, no par value\n\n \n\nIMDX\n\n \n\nThe Nasdaq Stock Market LLC\n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No\n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No\n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge accelerated filer ☐\n\nAccelerated filer ☐\n\nNon-accelerated filer ☒\n\nSmaller reporting company ☒\n\nEmerging growth company ☐\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No\n\nThe number of shares of issuer's common stock, no par value, outstanding as of May 6, 2026 was 32,290,167.\n\n \n\n \n\n \n\n[Table of Contents](#toc_page)\n\n \n\nINSIGHT MOLECULAR DIAGNOSTICS INC.\n\nTABLE OF CONTENTS\n\n \n\nFor the quarterly period ended March 31, 2026\n\n \n\n \n\nPage\n\n[CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS](#cautionary_note_regarding_forward_looki)\n\n2\n\n \n\n[PART I - FINANCIAL INFORMATION](#part_i)\n\n3\n\n \n\n[Item 1. Financial Statements](#item_1)\n\n3\n\n[CONDENSED CONSOLIDATED BALANCE SHEETS](#balance_sheets)\n\n3\n\n[UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS](#statements_of_operations)\n\n4\n\n[UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS](#statements_of_comprehensive_loss)\n\n5\n\n[UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ (DEFICIT) EQUITY](#shareholders_equity)\n\n6\n\n[UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS](#statements_of_cash_flows)\n\n7\n\n[NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS](#notes)\n\n8\n\n \n\n[Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations](#managements_discussion_and_analysis)\n\n40\n\n \n\n[Item 3. Quantitative and Qualitative Disclosures about Market Risk](#item_3)\n\n51\n\n \n\n[Item 4. Controls and Procedures](#item_4)\n\n52\n\n \n\n[PART II - OTHER INFORMATION](#part_ii)\n\n53\n\n \n\n[Item 1. Legal Proceedings](#item_1_legal)\n\n53\n\n \n\n[Item 1A. Risk Factors](#item_1a_risks)\n\n53\n\n \n\n[Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](#item_2_unregistered)\n\n53\n\n \n\n[Item 3. Defaults Upon Senior Securities](#item_3_defaults)\n\n53\n\n \n\n[Item 4. Mine Safety Disclosures](#item_4_mine)\n\n53\n\n \n\n[Item 5. Other Information](#item_5_other)\n\n53\n\n \n\n[Item 6. Exhibits](#item_6_exhibits)\n\n54\n\n \n\n[SIGNATURES](#signatures)\n\n55\n\n \n\n1\n\n[Table of Contents](#toc_page)\n\n \n\nCAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS\n\nCertain statements contained in this Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 (this “Report”) are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Insight Molecular Diagnostics Inc., or iMDx (f/k/a Oncocyte Corporation), along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Any statements that are not historical fact (including, but not limited to statements that contain words such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “seek,” “should,” “strategy,” “target,” “will,” “would” or similar expressions or the negative of such terms) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the businesses of iMDx, particularly those mentioned in this Report under “Risk Factors” and those Risk Factors in Part I, Item 1A. of our most recent Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the Securities and Exchange Commission (“SEC”). Except as required by law, iMDx undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.\n\nThe forward-looking statements include, among other things, statements about:\n\n•\nthe timing and potential achievement of future milestones;\n\n•\nthe timing and our ability to obtain and maintain coverage and reimbursements from the Centers for Medicare and Medicaid Services and other third-party payers, including within the U.S. and outside of the U.S.;\n\n•\nour plans to pursue research and development of diagnostic test candidates;\n\n•\nthe potential commercialization of diagnostic tests currently in development;\n\n•\nthe timing and success of future clinical research and the period during which the results of the clinical research will become available;\n\n•\nthe potential receipt of revenue from current sales of our diagnostic tests and/or diagnostic tests in development;\n\n•\nour assumptions regarding obtaining reimbursement and reimbursement rates of our current diagnostic tests and/or diagnostic tests in development;\n\n•\nour estimates regarding future orders of tests and our ability to perform a projected number of tests;\n\n•\nour estimates and assumptions around the patient populations, market size and price points for reimbursement for our diagnostic tests;\n\n•\nour estimates regarding future revenues, operating expenses, and future capital requirements;\n\n•\nour intellectual property position;\n\n•\nour ability to continue as a going concern;\n\n•\nour dependency on our collaboration with Bio-Rad Laboratories, Inc. for the development and commercialization of products;\n\n•\nthe impact of government laws and regulations, including the impact of a prolonged government shutdown; and\n\n•\nour competitive position.\n\nUnless the context otherwise requires, all references to “iMDx,” “we,” “us,” “our,” “the Company” or similar words refer to Insight Molecular Diagnostics Inc., together with our consolidated subsidiaries.\n\nThe description or discussion, in this Report, of any contract or agreement is a summary only and is qualified in all respects by reference to the full text of the applicable contract or agreement.\n\niMDx™, DetermaIO™, DetermaCNI™, GraftAssureCore™, GraftAssureIQ™ and GraftAssureDx™ are trademarks of iMDx, regardless of whether the “TM” symbol accompanies the use of or reference to the applicable trademark in this Report.\n\n2\n\n[Table of Contents](#toc_page)\n\n \n\nPART I - FINANCIAL INFORMATION"}